ABSTRACT OBJECTIVE: Corticotropin (ACTH)-independent hypercortisolism due to bilateral adrenocortical hyperplasia (BAH) in infancy is an extremely rare condition that is often caused by McCune Albright syndrome (MAS). MAS is caused by an activating mutation of the GNAS gene which leads to increased cyclic (c) adenosine monophosphate (AMP) signaling. Most forms of BAH are linked to increased cAMP signaling. We report the case of an infant with MAS who had BAH. METHODS: Genomic DNA fragments from blood and adrenal tissue encompassing regions (exons 8 and 9) with the hot spot activating missense GNAS mutations were amplified by classical bidirectional Sanger sequencing. RESULTS: The infant was found to carry the most common GNAS tissue, despite extensive skin and other findings. CONCLUSIONS: We conclude that infants with MAS, despite absence of the GNAS activating mutation in blood, may still have significant clinical findings, including ACTH-independent hypercortisolism. Molecular confirmation of the diagnosis should be sought at the tissue level in these patients.
INTRODUCTION
McCune Albright syndrome (MAS) is a very rare genetic disorder that is caused by activating mutations in the GNAS gene in a mosaic manner. 1 GNAS encodes the alpha subunit of the stimulatory G protein (Gsa) that regulates the synthesis of cyclic adenosine monophosphate (cAMP). 1 Activating GNAS mutations result in decreased GTPase activity of Gsa, constitu-tive activation of adenylate cylcase and, consequently, increased cAMP levels in all tissues where the GNAS mutations are present. 1, 2 Because of mosaicism, the manifestations are dependent on the distribution of the mutations. 1 MAS usually presents with a constellation of cutaneous (multiple café-au-lait spots), skeletal (polyostotic fibrous dysplasia) and endocrine manifestations (precocious puberty, growth hormone [GH] excess, hypercortisolism, hyperthyroidism and phosphate wasting). 3 Hypercortisolism in MAS is always ACTH-independent and leads to Cushing syndrome (CS), often mild and cyclical, but occasionally severe and with significant mortality. Onset of CS is usually in the first year of life and, very rarely, is congenital. The anatomical basis of CS has been attributed variously to bilateral nodular hyperplasia, 4 bilateral atypical adenomas, 5 bilateral macronodular disease 6 and other forms of bilateral hyperplasia. 7 Exceptionally, CS in the context of MAS resolves spontaneously. 8 We recently described primary bimorphic adrenocortical disease (PBAD) as the unifying descriptive term of the histopathology causing ACTH-independent CS in MAS. 10 In this report, we present the case of an infant that had intense clinical signs of MAS and ACTHindependent hypercortisolism suggesting widespread presence of the GNAS mutation. Still, repeated testing of blood cells did not show the presence of the causative GNAS mutation; on the other hand, the defect was present in both adrenal glands.
SUBJECTS & METHODOLOGY

Clinical investigations
MAS was diagnosed per standard criteria. 5 Written informed consent was obtained from the parents and the study was approved by the institutional review boards of the participating centers.
Genetic studies
DNA was extracted from peripheral blood leucocytes and adrenal tissue according to commercially available protocols (QIAGEN, Valencia, CA, USA). Genomic DNA fragments encompassing regions (exons 8 and 9) previously found to contain activating missense GNAS mutations (known as "gsp mutations") were amplified by classical bidirectional Sanger sequencing, as previously described, using the following primers: forward: 5'CAAGCAGGCTGACTATGTGC-3' and reverse: 5'-ACCACGAAGATGATGGCAGT-3'. This primer pair yielded a PCR product of 321bp. 9 Direct sequencing of the purified fragment was performed using the Genetic Sequencer ABI3500 (Applied Biosystems, Grand Island, USA).
RESULTS
Clinical case report
A female infant with uneventful perinatal and intrauterine history presented with tachycardia (200 beats per minute) at the age of 1 month. At the age of 2 months, the echocardiography showed signs of hypertrophic cardiomyopathy predominantly of the interventricular septum, obstruction of the left ventricle outflow tract and mitral insufficiency (grade 2-3). She had no clinical signs of heart failure except decreased oral intake and failure to thrive. Blood pressure was normal. Physical examination revealed persistent tachycardia with systolic murmur 3/6, pigmented lesions on head, trunk and extremities, with predilection on the left side, facial plethora and other signs of CS ( Figure 1A ). Laboratory tests revealed hyperthyroidism: TSH 0.008 mIU/l (normal range 0.460-7.300 mlU/l); fT4 44.29 pmol/l (normal range 8.50-24.00 pmol/l) and hypercortisolism with low or undetectable ACTH (ACTH 1 ng/l with a normal range of 7.2-63.3 ng/l). Radiological studies revealed fibrous dysplasia of both humerus and multiple ribs ( Figure 1B) . Magnetic resonance imaging (MRI) showed bilateral adrenal enlargement. The diagnosis of MAS was suspected based on clinical and laboratory findings and an appropriate treatment was initiated based on clinical manifestations. Clinical improvement was achieved within a few days from presentation after the initiation of thyreostatic therapy (thiamazole at an initial dose of 0.8 mg/kg/day) and beta-blockers (propranolol gradually increased to a dose of 4 mg/kg/day). Myocardial hypertrophy was also partially reversed. Bilateral adrenalectomy was performed at the age of 3 months. Adrenal histology revealed bilateral thickening of the adrenal cortex with irregular nodular conversion, consistent with PBAD. Substitution therapy was initiated with hydro-cortisone and fludrocortisone. At the age of 4 months, the patient developed signs of peripheral precocious puberty; an ovarian cyst on the right side was seen upon imaging (maximum diameter of 7.5 cm). A combination treatment of cyproterone acetate (initial dose of 2 mg/kg/day) and tamoxifen (initial dose of 1 mg/kg/day) was initiated with gradual regression of the cyst's size. MRI of the brain showed various abnormalities of the central nervous system (CNS): nonspecific signal focal alteration in the left thalamus and stripe signal changes in the dorsal brainstem and pons ( Figure 1C ), most likely corresponding to nonspecific neurodegeneration. Delayed myelination of brain and mild cortical and periventricular atrophy were also described. The patient died suddenly at 15 months of age in the course of a viral respiratory track infection probably due to adrenal crisis.
Genetic studies
Direct sequencing of the GNAS exons 8 and 9 of the patient's blood and adrenal DNA revealed normal sequence in the former, and the well-known heterozygous mutation in exon 8 (RefSeq NM_000516) from guanine to adenine (c.602G>A; rs121913495) in the latter. The c.602G>A GNAS mutation leads to an amino acid replacement in codon 201, from arginine (R) to histidine H (p.R201H) (Figure 2) .
DISCUSSION
We present the case of an infant with the classical triad of MAS (café-au-lait spots, polyostotic fibrous dysplasia and precocious puberty), as well as hyperthyroidism and CS due to PBAD, myocardial impairment and CNS abnormalities ( Figure 1A) . Despite the severity of the disease, and previous suggestions that in severe cases of MAS the causative GNAS mutation may be detectable in the blood, 1 the p.R201H defect was only found in one of the affected tissues (i.e. the adrenal cortex) but not in blood cells (Figure 2) .
GNAS-activating R201 mutations were first described in sporadic GH-secreting pituitary adenomas. 2 It has been shown that the replacement of arginine at position 201 of the GNAS protein with either cysteine or histidine causes a 30-fold decrease in intrinsic GTPase activity leading to high cAMP levels. 1 Since the mutation is only present post-zygotically, the extent of the disease is determined by the proliferation, migration and survival of the cells in which the mutation spontaneously occurred. 1 Thus, it makes sense that the mutation load should be reflected in the clinical presentation; yet, as the patient of this report demonstrates, this is not always the case.
Determining the extent of the presence of the mutation is important: the prognosis of patients with MAS varies considerably and it roughly corresponds to mutation load, which in turn determines the extent of organ involvement. In general, CNS, cardiac and hepatic involvement is associated with a poorer prognosis and even mortality, as our case demonstrates.
CS in infancy in the context of MAS is often severe, although a few cases with spontaneous remission have also been described. 8 PBAD associated with MAS is the most common cause of ACTH-independent CS due to BAH in infancy, 10 more frequent than PPNAD or isolated macronodular adrenal disease (iMAD) that are almost never seen in the first year of life. On the other hand, asymmetric enlargement of the adrenal gland in the context of MAS and ACTH-independent CS should be differentiated from adrenocortical cancer which is seen more frequently than MAS at this age, albeit also being a very rare occurrence. Li-Fraumeni or Beckwith-Widemann syndromes, adrenal tumors and ACTH-dependent CS should also be differentiated at this age from MAS.
In conclusion, we report the case of a child with severe MAS and CS due to PBAD who had no detectable load of the GNAS causative mutation (p.R201H) in her peripheral blood. The case illustrates the need for tissue examination when molecular confirmation of MAS is sought.
